Newswise — NEWARK, N.J. – Rutgers New Jersey Medical School (NJMS) has been selected by PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, as a Key Alliance Site. This status will give NJMS ongoing long-term access to clinical trial opportunities through PAREXEL’s broad client base in the pharmaceutical industry.
Under the agreement, NJMS will provide PAREXEL with the opportunity to place early to late phase studies, exposure to experienced investigators for clinical trial design and access to information resources through the NJMS electronic medical record system. This integrated arrangement will further enable PAREXEL and NJMS to plan, develop and execute clinical trial studies with shorter timelines.
“Our collaboration with PAREXEL will further strengthen the capabilities of New Jersey Medical School’s clinical research center unit, which conducts clinical trials in a wide variety of medical specialties,” says William C. Gause, senior associate dean for research at NJMS, which on July 1 became part of the newly created Rutgers Biomedical and Health Sciences unit within Rutgers. “With PAREXEL, NJMS looks forward to further developing our academic enterprise and biomedical research presence, as well as increasing patient recruitment and referrals. Most important, the long-term agreement will allow us to continue offering leading treatments and new medicines to patients in Newark and the rest of Essex County.”
"The agreement with PAREXEL exemplifies the university's enhanced commitment to collaborate with industry, and the growing awareness among leading companies that Rutgers is a strong partner,” says Kenneth Breslauer, vice president for health science partnerships at Rutgers. “There is much experience of successful clinical trials conducted with the schools that constitute what is now Rutgers Biomedical and Health Sciences, and we are pleased to see this new step forward. This partnership further enhances the global research, educational and service missions of the entire new Rutgers, as it strengthens both our clinical research capabilities and our potential to enhance health care delivery for the people throughout the state.”
Clinical trials hosted at the NJMS clinical research center unit will evaluate medications and other products designed to treat a wide range of conditions, including cancer, obesity and diabetes as well as cardiovascular, respiratory and infectious diseases. Many trials will be conducted through collaboration with University Hospital, the flagship teaching hospital for New Jersey Medical School.
“Ultimately, PAREXEL and NJMS are aligning and mobilizing knowledge and resources to bring new products to market through more efficient clinical trials,” said Lollo Eriksson, PAREXEL’s vice president, clinical research services and global site alliances.
Established in 1766, Rutgers, The State University of New Jersey, is America’s eighth oldest institution of higher learning and one of the nation’s premier public research universities. Serving more than 65,000 students on campuses, centers, institutes and other locations throughout the state, Rutgers is the only public university in New Jersey that is a member of the prestigious Association of American Universities.
Rutgers Biomedical and Health Sciences (RBHS) is the health care education, research and clinical division of Rutgers University, comprising nine schools and their attendant faculty practices, centers, institutes and clinics; New Jersey’s leading comprehensive cancer care center; and New Jersey's largest behavioral health care network.